Skip to Main Content

Organogenesis Holdings Inc. Securities Fraud Class Action

CompanyOrganogenesis Holdings Inc.
CourtUnited States District Court for the Eastern District of New York
Case Number21-cv-06845
Judge Honorable Diane Gujarati
Class PeriodJuly 22, 2020 through October 21, 2021
Security TypeSecurities

Case Background:

This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO) securities between August 10, 2020 and August 9, 2022, inclusive (the “Class Period”). 

Organogenesis primarily manufacturers and sells skin substitute products used in the treatment of chronic and acute wounds. During the Class Period, the complaint alleges that Defendants engaged in a scheme of marketing the difference, or “spread,” between how much Organogenesis charged physicians for two of its skin substitute products—Affinity and PuraPly XT—and the amount physicians were reimbursed by certain Medicare Administrative Contractors (“MAC”). Specifically, Defendants misrepresented and/or failed to disclose that: (1) the rapid increase in Affinity and PuraPly XT demand and sales in the physician offices was being driven by the Company’s marketing scheme; (2) Organogenesis’s competitive edge was entirely dependent on this unsustainable scheme; (3) Organogenesis was unable to effectively turnover its sales from the scheme to sales on the basis of the clinical benefits of its products; (4) which would lead to diminished demand and revenue once these products had an established  average selling price (“ASP”) set by Medicare (5) leading to a decline in Affinity sales that Organogenesis attributed to the operating market rather than the ASP; and (6) as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:

On March 29, 2024, the Court granted Defendants’ Motion to Dismiss. This action has concluded.

f you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Organogenesis Holdings Inc. (NASDAQ: ORGO) securities between March 17, 2021 and October 11, 2021.

Click here to print a PDF of this form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Organogenesis Holdings Inc. prior to the Class Period?
Are you a current or former employee of Organogenesis Holdings Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email